Biotech | May 19, 2022
Piramal Pharma Solutions new API plant in Canada goes online
It is part of the company's CAD $30 million capital investment in the Aurora, Canada site
It is part of the company's CAD $30 million capital investment in the Aurora, Canada site
Children 5 through 11 years of age are now authorized to receive a booster dose at least five months after the second dose of the two-dose primary series
Multiples is the first private equity (PE) investor in the company
Moderna continues to expand its mRNA platform for a range of additional clinical applications and routes of administration including a modality for lung delivery
Potential new treatment for progressive pulmonary fibrosis (PPF) builds on Boehringer Ingelheim’s leadership in lung fibrosis and will be further investigated in a phase III clinical trial program
AbbVie receives the option to license worldwide rights to CUG252 from Cugene, a clinical-stage and potential best-in-class Treg-selective IL-2 mutein, building on AbbVie's commitment to developing novel therapies in immunology
Tirzepatide is primarily indicated for the treatment of T2D and is expected to receive its decision from the FDA in Q2 2022
East Syracuse site to serve as the LOTTE Center for North America Operations for LOTTE’s biologics contract development and manufacturing organization (CDMO) business
The pharma companies will bring quality products at competitive prices to consumers in Oman and help bring down the cost of healthcare
India has the second-largest number of adults with diabetes globally, after China
Subscribe To Our Newsletter & Stay Updated
